News
2h
Zacks Investment Research on MSNHims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?Virtual healthcare services, or telehealth, are rapidly becoming a standard of care in the expanding digital healthcare space ...
Senate To Begin Marathon Vote Series On Trump's "Big, Beautiful Bill" As GOP Eyes July 4 Deadline The Senate is set to kick off what's expected to be a marathon session Monday, after the chamber ...
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...
1d
InsideHook on MSNCompounding Controversy Breaks Up Novo Nordisk-Hims & Hers PartnershipAs GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...
Novo Nordisk ends partnership with Hims & Hers, causing a 35% plunge. With no near-term catalysts, learn why investors must ...
Novo Nordisk is expanding access to its drug Wegovy through a new partnership with WeightWatchers, days after cutting ties with telehealth firm Hims & Hers. Starting July 1, WeightWatchers will ...
Under the deal, cash-paying patients can access a month’s supply of Wegovy through the Danish drugmaker’s Novocare pharmacy for $299. The one-time price will also be available through Novo’s other ...
Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...
Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results